PMC:7205724 / 1369-1518 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"51","span":{"begin":141,"end":144},"obj":"Gene"},{"id":"60","span":{"begin":74,"end":82},"obj":"Species"},{"id":"64","span":{"begin":98,"end":109},"obj":"Chemical"},{"id":"76","span":{"begin":88,"end":96},"obj":"Disease"}],"attributes":[{"id":"A51","pred":"tao:has_database_id","subj":"51","obj":"Gene:3569"},{"id":"A60","pred":"tao:has_database_id","subj":"60","obj":"Tax:9606"},{"id":"A64","pred":"tao:has_database_id","subj":"64","obj":"MESH:C502936"},{"id":"A76","pred":"tao:has_database_id","subj":"76","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"ID-19 correlated with severity, criticality, viral load, and prognosis of patients with COVID-19. Tocilizumab, a monoclonal antibody against IL6, cou"}

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T5","span":{"begin":124,"end":132},"obj":"Body_part"}],"attributes":[{"id":"A5","pred":"fma_id","subj":"T5","obj":"http://purl.org/sig/ont/fma/fma62871"}],"text":"ID-19 correlated with severity, criticality, viral load, and prognosis of patients with COVID-19. Tocilizumab, a monoclonal antibody against IL6, cou"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T17","span":{"begin":88,"end":96},"obj":"Disease"}],"attributes":[{"id":"A17","pred":"mondo_id","subj":"T17","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"ID-19 correlated with severity, criticality, viral load, and prognosis of patients with COVID-19. Tocilizumab, a monoclonal antibody against IL6, cou"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T5","span":{"begin":111,"end":112},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"}],"text":"ID-19 correlated with severity, criticality, viral load, and prognosis of patients with COVID-19. Tocilizumab, a monoclonal antibody against IL6, cou"}

{"project":"LitCovid-sample-MedDRA","denotations":[{"id":"T3","span":{"begin":45,"end":55},"obj":"http://purl.bioontology.org/ontology/MEDDRA/10022891"}],"attributes":[{"id":"A3","pred":"meddra_id","subj":"T3","obj":"http://purl.bioontology.org/ontology/MEDDRA/10062178"}],"text":"ID-19 correlated with severity, criticality, viral load, and prognosis of patients with COVID-19. Tocilizumab, a monoclonal antibody against IL6, cou"}

{"project":"LitCovid-sample-PD-NCBITaxon","denotations":[{"id":"T17","span":{"begin":88,"end":96},"obj":"Species"}],"attributes":[{"id":"A17","pred":"ncbi_taxonomy_id","subj":"T17","obj":"NCBItxid:2697049"}],"namespaces":[{"prefix":"NCBItxid","uri":"http://purl.bioontology.org/ontology/NCBITAXON/"}],"text":"ID-19 correlated with severity, criticality, viral load, and prognosis of patients with COVID-19. Tocilizumab, a monoclonal antibody against IL6, cou"}

{"project":"LitCovid-sample-Pubtator","denotations":[{"id":"60","span":{"begin":74,"end":82},"obj":"Species"},{"id":"76","span":{"begin":88,"end":96},"obj":"Disease"},{"id":"64","span":{"begin":98,"end":109},"obj":"Chemical"},{"id":"51","span":{"begin":141,"end":144},"obj":"Gene"}],"attributes":[{"id":"A64","pred":"pubann:denotes","subj":"64","obj":"MESH:C502936"},{"id":"A51","pred":"pubann:denotes","subj":"51","obj":"Gene:3569"},{"id":"A60","pred":"pubann:denotes","subj":"60","obj":"Tax:9606"},{"id":"A76","pred":"pubann:denotes","subj":"76","obj":"MESH:C000657245"}],"text":"ID-19 correlated with severity, criticality, viral load, and prognosis of patients with COVID-19. Tocilizumab, a monoclonal antibody against IL6, cou"}

{"project":"LitCovid-sample-UniProt","denotations":[{"id":"T177","span":{"begin":141,"end":144},"obj":"Protein"}],"attributes":[{"id":"A177","pred":"uniprot_id","subj":"T177","obj":"https://www.uniprot.org/uniprot/Q9XT80"},{"id":"A178","pred":"uniprot_id","subj":"T177","obj":"https://www.uniprot.org/uniprot/Q9UCU4"},{"id":"A179","pred":"uniprot_id","subj":"T177","obj":"https://www.uniprot.org/uniprot/Q9UCU3"},{"id":"A180","pred":"uniprot_id","subj":"T177","obj":"https://www.uniprot.org/uniprot/Q9UCU2"},{"id":"A181","pred":"uniprot_id","subj":"T177","obj":"https://www.uniprot.org/uniprot/Q9MZR1"},{"id":"A182","pred":"uniprot_id","subj":"T177","obj":"https://www.uniprot.org/uniprot/Q9MYZ7"},{"id":"A183","pred":"uniprot_id","subj":"T177","obj":"https://www.uniprot.org/uniprot/Q95KN6"},{"id":"A184","pred":"uniprot_id","subj":"T177","obj":"https://www.uniprot.org/uniprot/Q95181"},{"id":"A185","pred":"uniprot_id","subj":"T177","obj":"https://www.uniprot.org/uniprot/Q90YI0"},{"id":"A186","pred":"uniprot_id","subj":"T177","obj":"https://www.uniprot.org/uniprot/Q8MKH0"},{"id":"A187","pred":"uniprot_id","subj":"T177","obj":"https://www.uniprot.org/uniprot/Q8BN26"},{"id":"A188","pred":"uniprot_id","subj":"T177","obj":"https://www.uniprot.org/uniprot/Q865X6"},{"id":"A189","pred":"uniprot_id","subj":"T177","obj":"https://www.uniprot.org/uniprot/Q865W7"},{"id":"A190","pred":"uniprot_id","subj":"T177","obj":"https://www.uniprot.org/uniprot/Q6V919"},{"id":"A191","pred":"uniprot_id","subj":"T177","obj":"https://www.uniprot.org/uniprot/Q6L6X6"},{"id":"A192","pred":"uniprot_id","subj":"T177","obj":"https://www.uniprot.org/uniprot/Q5I6E3"},{"id":"A193","pred":"uniprot_id","subj":"T177","obj":"https://www.uniprot.org/uniprot/Q3UCQ0"},{"id":"A194","pred":"uniprot_id","subj":"T177","obj":"https://www.uniprot.org/uniprot/Q2MH06"},{"id":"A195","pred":"uniprot_id","subj":"T177","obj":"https://www.uniprot.org/uniprot/Q28819"},{"id":"A196","pred":"uniprot_id","subj":"T177","obj":"https://www.uniprot.org/uniprot/Q28747"},{"id":"A197","pred":"uniprot_id","subj":"T177","obj":"https://www.uniprot.org/uniprot/Q28319"},{"id":"A198","pred":"uniprot_id","subj":"T177","obj":"https://www.uniprot.org/uniprot/Q25BC2"},{"id":"A199","pred":"uniprot_id","subj":"T177","obj":"https://www.uniprot.org/uniprot/Q0PW36"},{"id":"A200","pred":"uniprot_id","subj":"T177","obj":"https://www.uniprot.org/uniprot/Q0GGL7"},{"id":"A201","pred":"uniprot_id","subj":"T177","obj":"https://www.uniprot.org/uniprot/Q08DT2"},{"id":"A202","pred":"uniprot_id","subj":"T177","obj":"https://www.uniprot.org/uniprot/P79341"},{"id":"A203","pred":"uniprot_id","subj":"T177","obj":"https://www.uniprot.org/uniprot/P51494"},{"id":"A204","pred":"uniprot_id","subj":"T177","obj":"https://www.uniprot.org/uniprot/P46650"},{"id":"A205","pred":"uniprot_id","subj":"T177","obj":"https://www.uniprot.org/uniprot/P41693"},{"id":"A206","pred":"uniprot_id","subj":"T177","obj":"https://www.uniprot.org/uniprot/P41683"},{"id":"A207","pred":"uniprot_id","subj":"T177","obj":"https://www.uniprot.org/uniprot/P41323"},{"id":"A208","pred":"uniprot_id","subj":"T177","obj":"https://www.uniprot.org/uniprot/P29455"},{"id":"A209","pred":"uniprot_id","subj":"T177","obj":"https://www.uniprot.org/uniprot/P26893"},{"id":"A210","pred":"uniprot_id","subj":"T177","obj":"https://www.uniprot.org/uniprot/P26892"},{"id":"A211","pred":"uniprot_id","subj":"T177","obj":"https://www.uniprot.org/uniprot/P20607"},{"id":"A212","pred":"uniprot_id","subj":"T177","obj":"https://www.uniprot.org/uniprot/P08505"},{"id":"A213","pred":"uniprot_id","subj":"T177","obj":"https://www.uniprot.org/uniprot/P05231"},{"id":"A214","pred":"uniprot_id","subj":"T177","obj":"https://www.uniprot.org/uniprot/O46568"},{"id":"A215","pred":"uniprot_id","subj":"T177","obj":"https://www.uniprot.org/uniprot/O35736"},{"id":"A216","pred":"uniprot_id","subj":"T177","obj":"https://www.uniprot.org/uniprot/O19007"},{"id":"A217","pred":"uniprot_id","subj":"T177","obj":"https://www.uniprot.org/uniprot/B6CKP4"},{"id":"A218","pred":"uniprot_id","subj":"T177","obj":"https://www.uniprot.org/uniprot/A9QWQ9"},{"id":"A219","pred":"uniprot_id","subj":"T177","obj":"https://www.uniprot.org/uniprot/A3FBE9"},{"id":"A220","pred":"uniprot_id","subj":"T177","obj":"https://www.uniprot.org/uniprot/A0S0B0"}],"text":"ID-19 correlated with severity, criticality, viral load, and prognosis of patients with COVID-19. Tocilizumab, a monoclonal antibody against IL6, cou"}

{"project":"LitCovid-sample-Enju","denotations":[{"id":"T207","span":{"begin":6,"end":16},"obj":"VBD"},{"id":"T208","span":{"begin":17,"end":21},"obj":"IN"},{"id":"T209","span":{"begin":22,"end":30},"obj":"NN"},{"id":"T210","span":{"begin":30,"end":31},"obj":"-COMMA-"},{"id":"T211","span":{"begin":32,"end":43},"obj":"NN"},{"id":"T212","span":{"begin":43,"end":44},"obj":"-COMMA-"},{"id":"T213","span":{"begin":45,"end":50},"obj":"JJ"},{"id":"T214","span":{"begin":51,"end":55},"obj":"NN"},{"id":"T215","span":{"begin":55,"end":56},"obj":"-COMMA-"},{"id":"T216","span":{"begin":57,"end":60},"obj":"CC"},{"id":"T217","span":{"begin":61,"end":70},"obj":"NN"},{"id":"T218","span":{"begin":71,"end":73},"obj":"IN"},{"id":"T219","span":{"begin":74,"end":82},"obj":"NNS"},{"id":"T220","span":{"begin":83,"end":87},"obj":"IN"},{"id":"T221","span":{"begin":88,"end":96},"obj":"NN"},{"id":"T222","span":{"begin":98,"end":109},"obj":"NNP"},{"id":"T223","span":{"begin":109,"end":110},"obj":"-COMMA-"},{"id":"T224","span":{"begin":111,"end":112},"obj":"DT"},{"id":"T225","span":{"begin":113,"end":123},"obj":"JJ"},{"id":"T226","span":{"begin":124,"end":132},"obj":"NN"},{"id":"T227","span":{"begin":133,"end":140},"obj":"IN"},{"id":"T228","span":{"begin":141,"end":144},"obj":"NN"},{"id":"T229","span":{"begin":144,"end":145},"obj":"-COMMA-"}],"relations":[{"id":"R199","pred":"arg1Of","subj":"T207","obj":"T208"},{"id":"R200","pred":"arg2Of","subj":"T209","obj":"T208"},{"id":"R201","pred":"arg1Of","subj":"T209","obj":"T210"},{"id":"R202","pred":"arg2Of","subj":"T211","obj":"T210"},{"id":"R204","pred":"arg2Of","subj":"T214","obj":"T212"},{"id":"R205","pred":"arg1Of","subj":"T214","obj":"T213"},{"id":"R206","pred":"arg1Of","subj":"T216","obj":"T215"},{"id":"R207","pred":"arg1Of","subj":"T212","obj":"T216"},{"id":"R208","pred":"arg2Of","subj":"T217","obj":"T216"},{"id":"R209","pred":"arg1Of","subj":"T217","obj":"T218"},{"id":"R210","pred":"arg2Of","subj":"T219","obj":"T218"},{"id":"R211","pred":"arg1Of","subj":"T219","obj":"T220"},{"id":"R212","pred":"arg2Of","subj":"T221","obj":"T220"},{"id":"R213","pred":"arg1Of","subj":"T222","obj":"T223"},{"id":"R214","pred":"arg2Of","subj":"T226","obj":"T223"},{"id":"R215","pred":"arg1Of","subj":"T226","obj":"T224"},{"id":"R216","pred":"arg1Of","subj":"T226","obj":"T225"},{"id":"R217","pred":"arg1Of","subj":"T226","obj":"T227"},{"id":"R218","pred":"arg2Of","subj":"T228","obj":"T227"}],"text":"ID-19 correlated with severity, criticality, viral load, and prognosis of patients with COVID-19. Tocilizumab, a monoclonal antibody against IL6, cou"}

{"project":"LitCovid-sample-PD-FMA","denotations":[{"id":"T5","span":{"begin":124,"end":132},"obj":"Body_part"}],"attributes":[{"id":"A5","pred":"fma_id","subj":"T5","obj":"http://purl.org/sig/ont/fma/fma62871"}],"text":"ID-19 correlated with severity, criticality, viral load, and prognosis of patients with COVID-19. Tocilizumab, a monoclonal antibody against IL6, cou"}

{"project":"LitCovid-sample-PD-MONDO","denotations":[{"id":"T17","span":{"begin":88,"end":96},"obj":"Disease"}],"attributes":[{"id":"A17","pred":"mondo_id","subj":"T17","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"ID-19 correlated with severity, criticality, viral load, and prognosis of patients with COVID-19. Tocilizumab, a monoclonal antibody against IL6, cou"}